Top Decliners on News: THRX, UNXL, AMBA, MELA

New York, NY -- (SBWIRE) -- 01/18/2013 -- Theravance Inc (NASDAQ:THRX) announced the pricing of $250 million aggregate principal amount of 2.125% convertible subordinated notes due 2023 in an underwritten public offering. The Company has also granted the underwriters an option to purchase up to $37.5 million aggregate principal amount of additional notes. The offering is scheduled to close on January 24, 2013. BofA Merrill Lynch is acting as the sole book-running manager for the offering. The notes will pay interest semiannually at a rate of 2.125% per annum.

The notes will be convertible at the option of the holders, at any time on or prior to the second business day preceding the maturity date, into shares of the Company's common stock at an initial conversion rate of 35.9903 shares of common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $27.79 per share. The initial conversion price represents a conversion premium of approximately 32.5% over the last reported sale price of $20.97 per share of the Company's common stock on the NASDAQ Global Select Market on January 17, 2013.

Should Investors Buy THRX Now? Free Sign Up Here For THRX Analyst Report

Uni-Pixel Inc (NDA) (NASDAQ:UNXL) shares increased 11.91% to $17.19. The company, last month, was vigorously denying allegations contained in litigation filed in the United Kingdom by UK-based Carclo PLC through its subsidiary, Conductive Inkjet Technology. In its filings before the English High Court, Conductive Inkjet Technology alleges that UniPixel made unauthorized use of CIT’s patented processes in developing catalytic ink and metallization technologies for touch-screen applications.

Can UNXL Rebound After The Recent Slump and Investors Can Make Money? Find Out Here

Ambarella, Inc. (NASDAQ:AMBA) is -1.15 - -9.13% from the previous close of $12.60. It traded between $11.25 - 12.75 with total traded volume of 461234 shares. Keep a close eye on AMBA , as the stock has been showing unusual moves over the past weeks. At Current market price, AMBA has recovered +106.31% from its 52-week Low of 5.55 and has Pulled back -14.68% from its 52-week high of 13.42.

Should Investor Buy OR Sell This Stock: CLICK HERE

MELA Sciences, Inc. (NASDAQ:MELA ) shares fell 6.60% to $1.98. The company announced that it will be participating in the upcoming Needham Growth Conference, being held January 15 – 17, 2013 at the Palace Hotel in New York. Joseph V. Gulfo, MD, MELA Sciences President and CEO will be presenting at the conference on Wednesday, January 16 at 10:00am ET.

How Should Investors Trade MELA After The Recent Fall? Find Out Here

DISCLAIMER
Neither PennyStocksUpdate.biz nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by PennyStocksUpdate.biz, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. PennyStocksUpdate.biz makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through PennyStocksUpdate.biz. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned here in..

Contact:
PennyStocksUpdate.biz
info@pennystocksupdate.bi AMBA